期刊
PIGMENT CELL & MELANOMA RESEARCH
卷 28, 期 3, 页码 -出版社
WILEY
DOI: 10.1111/pcmr.12340
关键词
diagnosis; immunotherapy; melanoma; metastasis; pathology; PD-1; PD-L1; prognosis; biomarker; heterogeneity
资金
- Cameron Fellowship through Melanoma Institute Australia
- National Health and Medical Research Council Fellowship program
- National Health and Medical Research Council
- Cancer Institute New South Wales
- Melanoma Foundation of the University of Sydney
- Melanoma Institute Australia
This study evaluated the expression of PD-L1 in immunotherapy-naive metastatic melanoma patients to determine longitudinal intrapatient concordance and correlate PD-L1 status with clinicopathologic characteristics and outcome. PD-L1 expression was assessed by immunohistochemistry in 58 patients (43 primary tumors, 96 metastases). Seventy-two percent of patients had at least one specimen expressing PD-L1 in 1% of tumor cells. Median positive tumor cell count overall was low (8% in nonzero specimens). PD-L1 expression was frequently discordant between primary tumors and metastases and between intrapatient metastases, such that 23/46 longitudinal patient specimens were discordant. PD-L1 was associated with higher TIL grade but not with other known prognostic features. There was a positive univariate association between PD-L1 expression in locoregional metastases and melanoma-specific survival, but the effect was not observed for primary melanoma. In locoregional lymph node metastasis, PD-L1+/TIL+ patients had the best outcome, and PD-L1+/TIL- patients had poor outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据